All In Biotech

Drug Trial Radar · NCT06409481

Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

Last checked: Nov 20, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

800,000

Planned (sponsor's estimate)

Start

Jun 1, 2024

Primary completion

Jun 30, 2024

Study completion Oct 30, 2024

Sponsor

Lead sponsor
The First Affiliated Hospital of Xinxiang Medical CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 10, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this observational study is to explore and analyze reports of cardiac or vascular adverse events linked to the administration of antineoplastic agents among patients diagnosed with tumors represented by advanced non-small cell lung cancer. The study leverages pharmacovigilance databases such as the World Health Organization (WHO) database (VigiBase), FDA Adverse Event Reporting System (FAERS), and others to gather individual safety case reports for analysis.

Conditions

  • Cardiovascular Diseases
  • Cardiac Diseases
  • Vascular Diseases
  • Cancer

Interventions

  • Antineoplastic AgentsDrug

    small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cardio-vascular toxicity of antineoplastic agentsTime frame: Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.